Pathwork® Diagnostics develops and delivers innovative molecular diagnostics for oncology.
The company’s Pathwork Tissue of Origin Test is a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. It is the only FDA-cleared and Medicare-covered molecular test of its kind. The company provides the Tissue of Origin Test through its CLIA-certified laboratory.
Pathwork Tissue of Origin Test is now covered by Medicare.
As of June 2011 Pathwork Diagnostics, Inc., is covered by Medicare. Because all Tissue of Origin Test specimens are processed in the Pathwork Diagnostics Laboratory in California, the Palmetto decision means that the test will be covered for Medicare patients across the nation.
Learn More
Pathwork Diagnostics offers mutation testing for evaluating response to targeted therapies
Pathwork Diagnostics Laboratory offers KRAS, BRAF and EGFR mutation testing to help clinicians determine whether patients will respond to targeted therapies for colorectal cancer, non-small cell lung cancer, and melanoma.
Learn More
